Kalaris Therapeutics Unveils Phase 1 Data for TH103 in Neovascular AMD at Macula Society Meeting
I'm PortAI, I can summarize articles.
Kalaris Therapeutics Inc. will present Phase 1 clinical data for TH103, a dual-targeting VEGF and HSPG inhibitor, at the Macula Society's 49th Annual Meeting on February 26, 2026, in San Diego. The presentation will focus on safety, tolerability, pharmacokinetics, and early efficacy outcomes in patients with treatment-naive neovascular age-related macular degeneration. Results have not yet been disclosed.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments